CD8A and neoplasm: Furthermore, existing knowledge of somatic mutations involved in resistance to targeted therapies74 or the role of immune cells (i.e., CD8 T cells) in tumor growth, metastasis, and resistance to immunotherapy89 could be leveraged to develop radiomic signatures that predict resistance to therapy.